PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: DNAC) is a clinical-stage biopharmaceutical company developing autologous renal cell therapy for patients with chronic kidney disease, with its lead program REACT targeting individuals whose CKD is driven by type 2 diabetes. The company entered public markets through a SPAC business combination, completing its de-SPAC transaction and listing on Nasdaq in 2022. Operating at the intersection of regenerative medicine and nephrology, ProKidney has maintained an active SEC filing record since its debut as a publicly traded company, including an 8-K submission filed June 30, 2023. Investors and analysts tracking SPAC-origin healthcare and biotech names can access ProKidney's full profile, filing history, and peer data by signing up at SpacDesk.